Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
Regeneron Pharmaceuticals (NASDAQ: REGN) has secured its sixth consecutive position in the Dow Jones Sustainability World Index (DJSI World) and fifth consecutive inclusion in the DJSI North America Index. The company ranks in the top 1% of global biotechnology companies, being one of only six biotech firms globally in the DJSI World Index.
The company's success stems from significant achievements in Societal Healthcare, Human Capital Management, and Corporate Governance. Their responsibility strategy focuses on three key areas: improving lives of people with serious diseases, fostering integrity and excellence, and building sustainable communities. Regeneron is on track to meet its 2025 goals, which include developing ~40 investigational medicines, implementing responsible AI practices, ensuring global pay equity, and enhancing treatment access in lower-income countries.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha ottenuto la sua sesta posizione consecutiva nell'Indice di Sostenibilità Mondiale Dow Jones (DJSI World) e il quinto inserimento consecutivo nell'Indice DJSI Nord America. L'azienda si colloca nel 1% migliore delle aziende biotecnologiche globali, essendo una delle sole sei aziende biotecnologiche a livello mondiale nell'Indice DJSI World.
Il successo dell'azienda deriva da significativi traguardi nella Sanità Sociale, nella Gestione del Capitale Umano e nella Governance Aziendale. La loro strategia di responsabilità si concentra su tre aree chiave: migliorare la vita delle persone affette da gravi malattie, promuovere integrità ed eccellenza e costruire comunità sostenibili. Regeneron è sulla buona strada per raggiungere i suoi obiettivi del 2025, che includono lo sviluppo di circa 40 farmaci in fase di sperimentazione, l'implementazione di pratiche di intelligenza artificiale responsabile, l'assicurazione di parità retributiva globale e il miglioramento dell'accesso ai trattamenti nei paesi a basso reddito.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha asegurado su sexta posición consecutiva en el Índice de Sostenibilidad Mundial Dow Jones (DJSI World) y su quinta inclusión consecutiva en el Índice DJSI América del Norte. La compañía ocupa el top 1% de las empresas biosanitarias globales, convirtiéndose en una de las seis firmas biotecnológicas a nivel mundial en el Índice DJSI World.
El éxito de la empresa proviene de logros significativos en Atención Sanitaria Social, Gestión del Capital Humano y Gobernanza Corporativa. Su estrategia de responsabilidad se centra en tres áreas clave: mejorar la vida de las personas con enfermedades graves, fomentar la integridad y la excelencia, y construir comunidades sostenibles. Regeneron está en camino de cumplir sus objetivos de 2025, que incluyen el desarrollo de ~40 medicamentos en investigación, la implementación de prácticas de IA responsable, la garantía de equidad salarial global y la mejora del acceso al tratamiento en países de bajos ingresos.
레제너론 제약 (NASDAQ: REGN)은 다우존스 지속가능성 세계지수(DJSI World)에서 여섯 번째 연속 포지션을 확보했으며, 다우존스 북미지수에서도 다섯 번째 연속 포함되었습니다. 이 회사는 전 세계 생명공학 회사 중 상위 1%에 해당하며, DJSI 세계지수에 포함된 여섯 개의 생명공학 회사 중 하나입니다.
회사의 성공은 사회적 건강 관리, 인적 자본 관리, 그리고 기업 거버넌스에서의 중요한 성과에서 비롯됩니다. 그들의 책임 전략은 세 가지 주요 영역에 초점을 맞추고 있습니다: 중병에 걸린 사람들의 삶을 개선하고, 정직성과 우수성을 촉진하며, 지속 가능한 커뮤니티를 만드는 것입니다. 레제너온은 2025년 목표를 달성할 수 있는 길에 있으며, 여기에는 약 40개의 연구 의약품 개발, 책임 있는 인공지능 관행 도입, 글로벌 급여 공정성 보장, 저소득 국가의 치료 접근성 향상이 포함됩니다.
Regeneron Pharmaceuticals (NASDAQ: REGN) a obtenu sa sixième position consécutive dans le Dow Jones Sustainability World Index (DJSI World) et sa cinquième inclusion consécutive dans l'indice DJSI Amérique du Nord. L'entreprise se classe dans le top 1% des entreprises biopharmaceutiques mondiales, étant l'une des six seules entreprises biopharmaceutiques au monde dans l'indice DJSI World.
Le succès de la société découle d'importantes réalisations dans les domaines de la santé sociétale, de la gestion des ressources humaines et de la gouvernance d'entreprise. Leur stratégie de responsabilité se concentre sur trois domaines clés : améliorer la vie des personnes atteintes de maladies graves, favoriser l'intégrité et l'excellence, et construire des communautés durables. Regeneron est sur la bonne voie pour atteindre ses objectifs de 2025, qui incluent le développement d'environ 40 médicaments expérimentaux, la mise en œuvre de pratiques d'IA responsables, l'assurance de l'équité salariale mondiale et l'amélioration de l'accès aux traitements dans les pays à faible revenu.
Regeneron Pharmaceuticals (NASDAQ: REGN) hat seine sechste aufeinanderfolgende Position im Dow Jones Nachhaltigkeitsweltindex (DJSI World) sowie die fünfte aufeinanderfolgende Aufnahme im DJSI Nordamerika-Index gesichert. Das Unternehmen zählt zu den Top 1% der globalen Biotechnologieunternehmen und ist eines von nur sechs Biotech-Firmen weltweit im DJSI World Index.
Der Erfolg des Unternehmens ist auf bedeutende Errungenschaften im Bereich der gesellschaftlichen Gesundheitsversorgung, des Humankapitalmanagements und der Unternehmensführung zurückzuführen. Ihre Verantwortungstrategie konzentriert sich auf drei Schlüsselbereiche: die Lebensqualität von Menschen mit schweren Krankheiten zu verbessern, Integrität und Exzellenz zu fördern und nachhaltige Gemeinschaften aufzubauen. Regeneron ist auf dem besten Weg, seine Ziele für 2025 zu erreichen, die die Entwicklung von etwa 40 Prüfmedikamenten, die Implementierung verantwortungsvoller KI-Praktiken, die Gewährleistung globaler Lohngleichheit und die Verbesserung des Zugangs zu Behandlungen in einkommensschwachen Ländern umfassen.
- None.
- None.
TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI World) and fifth consecutive inclusion in the Dow Jones Sustainability North America Index (DJSI North America). These rankings highlight the company’s leadership in adopting responsible practices that drive business resilience and improve our world.
The DJSI World Index is a leading benchmark for corporate responsibility, recognizing the top 10 percent of the world’s most sustainable companies in each industry. Regeneron stands out as one of only six biotechnology firms globally included in the index. Furthermore, this year, Regeneron’s score placed it in the top 1 percent of all rated biotechnology companies worldwide, reflecting Regeneron’s significant advancements in Societal Healthcare, Human Capital Management and Corporate Governance.
“Regeneron’s approach to corporate responsibility is grounded in our company’s values and mission. We take a long-term view and prioritize issues that matter most to our business and stakeholders, which include patients, investors and colleagues around the world,” said Leonard S. Schleifer, M.D., Ph.D., co-founder, Board co-Chair, President, and Chief Executive Officer of Regeneron. “Guided by our commitment to ‘Do Well by Doing Good,’ we are broadening access to our medicines, maintaining the highest ethical standards, and helping protect and restore the planet, in turn helping millions of people and growing sustainably. Our repeated inclusion in the DJSI World Index validates our approach and the innovative efforts of our team.”
Regeneron’s responsibility strategy, which is intentionally and inextricably linked to its business strategy, is focused on three key areas: improving the lives of people with serious diseases, fostering a culture of integrity and excellence, and building sustainable communities.
The company’s annual Responsibility Report transparently details progress toward its 2025 global goals, such as advancing a robust clinical pipeline of ~40 investigational medicines, a new position statement on responsible artificial intelligence practices, data on global pay equity, efforts to enhance access to its Ebola treatment in lower- and middle-income countries, and more. Regeneron is positioned to meet or exceed its 2025 goals and is working to define future targets that reflect its mission of bringing important new medicines to people with serious diseases.
“Regeneron’s consistent and high rankings on prestigious environmental, social and governance indices reflect progress toward our 2025 goals and our dedication to leveraging science to improve lives, our communities and the planet,” said Christina Chan, Senior Vice President of Corporate Affairs at Regeneron. “We are committed to setting new standards for responsible innovation and growth that will carry both our industry and society forward.”
Regeneron’s commitment to corporate responsibility is demonstrated through its strong performance in top environmental, social and governance (ESG) ratings and rankings. In addition to being included in the DJSI World and North America indices, Regeneron is also recognized in the Sustainalytics Risk Rating, the ISS ESG Corporate Rating, and the FTSE4Good Index Series. Each of these recognitions underscore Regeneron's continued efforts to anticipate and address ESG risks and opportunities.
| Rating | Industry Ranking1 |
| S&P Global Corporate Sustainability Assessment | Top |
| Sustainalytics Risk Rating | Top |
| ISS ESG Corporate Rating | Top |
| FTSE4Good Index Series | Top |
1 As of Dec 13, 2024
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included in the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono and matching gift programs. Our most significant philanthropic commitments are in the area of early science education, including the Regeneron Science Talent Search and the Regeneron International Science and Engineering Fair (ISEF).
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
Media Contacts:
Joseph Brown, Regeneron
386-283-1323
Joseph.Brown2@regeneron.com
FAQ
What significant ESG achievement did Regeneron (REGN) announce in December 2024?
How many biotechnology companies globally are included in the DJSI World Index with Regeneron (REGN)?
What are Regeneron's (REGN) key 2025 responsibility goals?
How does Regeneron (REGN) rank in major ESG ratings as of December 2024?
What are the three key focus areas of Regeneron's (REGN) responsibility strategy?
